On January 8, 2016, Timothy P. Walbert, Horizon Pharma's chairman, president and chief executive officer, assumed primary responsibility for management of the commercial organization and direct management of each of the commercial business unit general managers. Accordingly, the company has eliminated the chief commercial officer role and subsequently terminated John Kody, executive vice president, chief commercial officer.
Horizon Therapeutics Public Limited Company
Equities
HZNP
IE00BQPVQZ61
Pharmaceuticals
1st Jan change | Capi. | |
---|---|---|
+57.02% | 848B | |
+31.64% | 627B | |
-0.08% | 363B | |
+15.43% | 318B | |
+12.56% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.38% | 179B | |
+3.42% | 167B |